Psoriasis is a chronic, inflammatory disease characterized by red, scaly, itchy patches of skin. Although there is currently no cure for psoriasis, patients are prescribed treatments aimed at managing the symptoms, namely regulating the immune system and/or reducing the rapid rate of skin cell proliferation. As new therapies are being developed, it would be helpful to have a method that would predict the effectiveness of these treatments in patients. Therefore, the Seeker desires a biomarker early in the course of therapy that is generalizable and predictive of efficacy later in the course of treatment.
This Theoretical Challenge requires only a written proposal.
As reported by the World Health Organization, more than 100 million are affected by psoriasis globally. A noncommunicable disease of the skin, psoriasis presents in several different forms, which can be disfiguring and painful. Patients suffer not only physically, but due to the high visibility of skin lesions, they must also deal with emotional and social issues. Symptom control may be achieved with the administration of topical or systemic medications or by phototherapy, yet there is no cure. Changes in the biomarkers early in the course of therapy, which could predict subsequent clinical response, would be very useful in psoriasis, both in clinical practice and in clinical trials/clinical development of new therapies. Therefore, the Seeker desires an early biomarker that is predictive of treatment efficacy.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, the Solvers will not have to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a non-exclusive license to practice their solutions.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on March 26, 2017.
Late submissions will not be considered.
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.
What is a Theoretical-Licensing Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.